NIGHTSTAR THERAPEUTICS
NightstaRx Ltd. is a U.K. startup company. Gene therapy is the use of a gene to treat disease. The approach could enable treatments for a several rare conditions caused by mutations in a single gene.
NIGHTSTAR THERAPEUTICS
Industry:
Biotechnology Genetics Health Diagnostics
Founded:
2013-01-01
Address:
London, England, United Kingdom
Country:
United Kingdom
Website Url:
http://www.nightstartx.com
Total Employee:
11+
Status:
Closed
Contact:
+442076112077
Email Addresses:
[email protected]
Total Funding:
174.59 M USD
Technology used in webpage:
SPF Microsoft Exchange Online Office 365 Mail IPv6 Microsoft Azure DNS CookieYes For WordPress Akamai Hosted Proofpoint KnowBe4 Wordpress 5.0
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
New Enterprise Associates
New Enterprise Associates investment in Series C - Nightstar Therapeutics
Redmile Group
Redmile Group investment in Series C - Nightstar Therapeutics
Syncona Partners LLP
Syncona Partners LLP investment in Series C - Nightstar Therapeutics
Wellington Management
Wellington Management investment in Series C - Nightstar Therapeutics
Syncona Partners LLP
Syncona Partners LLP investment in Series B - Nightstar Therapeutics
New Enterprise Associates
New Enterprise Associates investment in Series B - Nightstar Therapeutics
Syncona Partners LLP
Syncona Partners LLP investment in Series A - Nightstar Therapeutics
Official Site Inspections
http://www.nightstartx.com
- Host name: 198.180.131.91
- IP address: 198.180.131.91
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Nightstar Therapeutics"
Nightstar Therapeutics - Crunchbase Company Profile & Funding
NightstaRx Ltd. is a U.K. startup company. Gene therapy is the use of a gene to treat disease. The approach could enable treatments for a several rare conditions caused by mutations in a …See details»
NightstaRx Company Profile 2024: Valuation, Investors ... - PitchBook
Developer of a gene therapy platform designed to maintain and restore sight in patients with inherited retinal dystrophies.See details»
Nightstar (NightstaRx Ltd) - VentureRadar
Nightstar is a biopharmaceutical company focused on the development and commercialisation of therapies for retinal dystrophies. Its lead programme is a retinal gene therapy for …See details»
NIGHTSTAR THERAPEUTICS: Contact Details and Business Profile
Nightstar Therapeutics plc (NASDAQ: NITE) is a leading clinical-stage gene therapy company focused on developing and commercializing novel one-time treatments for patients suffering …See details»
Nightstar Therapeutics plc | Insights
Jul 4, 2024 · Already A Biomedtracker Subscriber? You have access to the full company record through your subscription.See details»
Nightstar - Company Profile - Tracxn
Nov 18, 2024 · Developer of gene therapies for retinal diseases. The company's lead retinal gene therapy NSR-REP1 (Orphan Drug Designated by both the US FDA and EMA) is targeted for …See details»
NIGHTSTAR THERAPEUTICS Management Team | Org Chart
Nightstar Therapeutics plc (NASDAQ: NITE) is a leading clinical-stage gene therapy company focused on developing and commercializing novel one-time treatments for patients suffering …See details»
Nightstar Therapeutics - Craft
Nightstar Therapeutics (formerly known as NightstaRx) is a clinical-stage gene therapy company focused on developing and commercializing novel one-time treatments for patients suffering …See details»
Nightstar Therapeutics PLC Completion of Acquisition by
Jun 7, 2019 · Accordingly, the Scheme has now become Effective in accordance with its terms and the entire issued and to be issued share capital of Nightstar has been acquired by …See details»
Nightstar Therapeutics plc reaches agreement to be acquired
Mar 4, 2019 · Nightstar is a leading clinical-stage gene therapy company focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal …See details»
Recommended Acquisition of Nightstar Therapeutics plc by
Apr 9, 2019 · Investors may obtain a free copy of the Scheme Document at the SEC’s website at www.sec.gov, or free of charge from Nightstar at https://www.nightstartx.com or by directing a …See details»
Oxford University and Syncona announce the formation of …
Jan 31, 2014 · Syncona LLP, an independent subsidiary of the Wellcome Trust, announces a £12 million investment in NightstaRx Ltd ("Nightstar") a spin-out from the University of Oxford and …See details»
Nightstar Therapeutics To Present New Data in Choroideremia
Apr 23, 2018 · Nightstar Therapeutics plc (NASDAQ: NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal diseases, today announced that one …See details»
NightstaRx Appoints Ophthalmology Industry Veteran Scott
Oct 6, 2022 · NightstaRx Ltd (“Nightstar”), a biopharmaceutical company specializing in developing gene therapies for inherited retinal dystrophies, today announced the appointment …See details»
Nightstar Raises $45 Million to Fund Development of Gene
Jun 29, 2017 · NightstaRx Limited (“Nightstar”), a late-stage biopharmaceutical company developing gene therapies for inherited retinal diseases, today announced the completion of a …See details»
Nightstar Expands Pipeline with Novel Gene Therapy for the
Nov 8, 2017 · Nightstar is a leading clinical-stage gene therapy company focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal …See details»
NightstaRx Ltd. - Drug pipelines, Patents, Clinical trials - Synapse
Purpose: We report a novel finding on spectral domain optical coherence tomography in patients with choroideremia, which we describe as scleral pits (SCPs).See details»
Nightstar Therapeutics plc Announcement of Expiry of HSR
Apr 16, 2019 · Investors may obtain a free copy of the Scheme Document at the SEC’s website at www.sec.gov, or free of charge from Nightstar at https://www.nightstartx.com or by directing a …See details»
U.S. Investigating Political Action Committee Tied to Mayor Adams
1 day ago · Prosecutors and the F.B.I. are examining an organization founded by the Rev. Alfred Cockfield II, according to people with knowledge of the matter. By William K. Rashbaum Dana …See details»
NightstaRx Commences first Phase I/II Gene Therapy Clinical
Mar 20, 2017 · LONDON-- (BUSINESS WIRE) -- NightstaRx Ltd (“Nightstar”), a biopharmaceutical company specialising in developing gene therapies for inherited retinal …See details»